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Novel rod-like mesoporous silica nanoparticles with a rough 
surface have been prepared with 37% higher cellular uptake 
and drug delivery efficacy compared to their counterpart 
with a smooth surface. 
Delivery of various drugs into target cells is crucial in modern 10 
medicine.1, 2 Some free drugs, e.g. hydrophobic molecules, are 
poorly delivered to the cells due to intrinsic issues such as low 
solubility and/or unwanted toxicity.1 To circumvent these 
problems, various nanoparticle based drug delivery systems 
(DDS), prepared by liposomes, lactic acid, peptide, chitosan, 15 
polymers, carbon, silica, etc,1-3 have been developed. The 
positive effect of DDS on the stability of drugs has also been 
demonstrated.4 Among them, mesoporous silica nanoparticles 
(MSN) have attracted great attention5 due to their unique features 
including good biocompatibility,6, 7 ordered pore network,8, 9 20 
tunable surface chemistry,10 and high drug loading capacity.9, 11 
Many studies focused on the impacts of particles size,12-14 
shape,15-18 surface chemical modification10, 19 on the cellular 
uptake and delivery performance. Bare silica has relatively low 
cellular uptake capability, hence surface functionalization of 25 
MSN with positively charged groups such as amine group,19, 20 
poly ethylene imine (PEI)21 and poly-L-lysine (PLL)22 have been 
studied to enhance the interaction with negatively charged cell 
membranes. However, MSN after functionalization are generally 
toxic, limiting their use in the clinical setting. It remains a 30 
challenge to further improve the delivery efficiency of MSN with 
a pure silica composition. 23 
The rapid development of bio-inspired and bio-mimetic 
chemistry has provided new approaches for the rational design of 
functional nanomaterials with enhanced performance. In nature, 35 
after millions of years’ evolution, viruses have developed very 
efficient ways to enter cells. For example, virus in Rhabdoviridae 
family with characteristic rod-like shape can infect a broad range 
of hosts including humans.24 It is noted that rod-like MSN have 
been studied as nano-carriers with excellent cellular uptake 40 
efficacy.16, 17, 25 On the other hand, most viruses including 
rhabdovirus have rough surface with spikes located on the outer 
membranes.24 Previous studies26-28 have successfully proved that 
nano-scale surface roughness enhances the cellular uptake of 
solid nanoparticles. However, there is no report to apply this 45 
concept in the synthesis of MSNs to improve the cellular uptake  
 
 
Fig. 1  TEM images of R-MCM-41(A, C) and RR-MCM-41(B, D). The 
fringes indicated by dark arrows correspond to (10) plane of the 50 
hexagonal structure. Scale bar in A, B: 200 nm; scale bar in C, D: 100nm. 
and drug delivery performance. 
In this communication, we report the synthesis and cellular 
delivery performance of novel rod-like MSN with a rough 
surface. MCM-41 type MSN with a rod-like morphology 55 
(denoted R-MCM-41) were prepared using our reported 
protocol29 (see †ESI), using cetyltrimethylammonium bromide 
and perfluorooctanoic acid as co-templated and tetraethyl 
orthosilicate as the silica source. The as-synthesised products 
were functionalized with amino group, followed by conjugation 60 
with negatively charged silica shell particles with small size 
(~13nm) prepared by a modified Stöber method,30 forming rough 
R-MCM-41 (denoted RR-MCM-41). The final products were 
calcined at 550 °C for both R-MCM-41 and RR-MCM-41, 
ensuring that the two materials under study have the same pure 65 
silica composition. 
Figure 1 shows the transmission electron microscopy (TEM) 
images of both R-MCM-41 (Fig. 1A&C) and RR-MCM-41(Fig  
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Fig. 2  Cellular uptake of R-MCM-41 and RR-MCM-41. Confocal 
microscopy images (A & B) show the localisation of RITC (red color) in 
KHOS cell line delivered by R-MCM-41(A) and RR-MCM-41(B). The nuclei 
are stained in blue (DAPI) and the cytoplasm in green (FITC).FACS 5 
analysis (C) and comparison of the normalised MFI (D) indicate that RR-
MCM-41-FITC has higher cellular uptake efficiency than R-MCM-41-FITC 
after 4h. Scale bar in A, B: 10µm. 
.1B&D). R-MCM-41 possesses a rod-like morphology with an 
average aspect ratio of 3:1 (Fig. 1A). The fringes indicated by the 10 
dark arrows in Fig. 1C correspond to (10) plane of hexagonal 
structure, in accordance with our previous report.29 The rod-like 
morphology is retained in RR-MCM-41, while the outer surface 
is uniformly coated by small silica spheres (Fig. 1B&D). The (10) 
fringes can also be observed as indicated by the black arrows in 15 
RR-MCM-41 (Fig. 1D). 
The small angle X-ray diffraction pattern of R-MCM-41 (Fig. 
S1A, †ESI) shows three well-resolved peaks at 2θ of 2.35, 4.08 
and 4.70° , which can be indexed as the 10, 11, and 20 reflections 
based on a two-dimensional hexagonal symmetry (p6mm). For 20 
RR-MCM-41, three diffractions are also observed but the 
intensity is much weaker compared to R-MCM-41 due to the 
existence of shell particles on the surface. Nitrogen adsorption-
desorption measurements (Fig. S1B, Tab. S1) show that the RR-
MCM-41 has a decreased BET surface area (613 m2/g) compared 25 
to R-MCM-41 (703 m2/g) because the shell particles are solid and 
have comparatively lower surface area than R-MCM-41. An 
increase in the total pore volume is observed for RR-MCM-41 
(0.85 cm3/g) compared to R-MCM-41 (0.59 cm3/g), which is 
mainly contributed by the inter-particles packing voids as shown 30 
in the capillary condensation step at the relative pressure (P/P0) 
higher than 0.9. The pore size of RR-MCM-41 is calculated to be 
2.5 nm (Fig. S1C), slightly larger than R-MCM-41 (2.2 nm), 
which is caused by the hydrothermal treatment during the amino 
group modification step. 35 
To compare the cellular uptake efficiency, R-MCM-41 and 
RR-MCM-41 were both labelled with a red fluorescent dye, 
Rhodamine B isothiocyanate (RITC), or with another green 
fluorescent dye, fluorescein 5(6)-isothiocyanate dye (FITC),  
 40 
Fig. 3  In Vitro cytotoxicity of R-MCM-41 CUR and RR-MCM-41 CUR in 
KHOS cell line after 24h incubation.  
using post-synthesis grafting methods (†ESI). The dye conjugated 
particles were incubated with KHOS, a human osteosarcoma cell 
line for 4 h. Confocal microscopy images (Fig. 3A, B) show that 45 
in either RITC (Fig. 2A&B) or FITC conjugated systems (Fig. 
S2) fluorescent signals with higher intensity are observed in RR-
MCM-41 group compared to R-MCM-41, indicating that the 
rough particles have improved cellular uptake performance. 
To quantitatively evaluate the cellular uptake efficiency of 50 
these two particles, fluorescence-activated cell sorting (FACS) 
analysis were used and median fluorescence intensity (MFI) were 
adopted to reflect the relative amount of internalized particles. 
MSN modified with FITC are used in this study and the grafting 
FTIC amount in both R-MCM-41 and RR-MCM-41 were tested 55 
to normalize MFI (Table. S2, †ESI). It is shown that RR-MCM-
41 exhibits 37% higher cellular uptake efficiency than R-MCM-
41 (Fig. 3C, D), in accordance with the confocal microscopy 
studies. 
 To compare the performance of R-MCM-41 and RR-MCM-41 60 
as effective drug carriers, a hydrophobic drug, curcumin, is 
loaded into both particles by rotary evaporation method (see 
†ESI). From the thermogravimetric analysis (Fig. S3), it shows 
that the weight percentage of curcumin is 29.0% and 25.7% for 
RR-MCM-41 and R-MCM-41, respectively. 65 
To confirm whether the drug molecules are loaded inside the 
pores, Fourier transform infrared spectroscopy (FTIR) and 
differential scanning calorimetry (DSC) technique is employed. 
As shown in Fig. S4, the peaks in the area of 1450-1630 cm−1 in 
R-MCM-41 CUR and RR-MCM-41 CUR come from the C=O 70 
and C=C group of curcumin. For DSC results (Fig. S5), pure 
curcumin (CUR) shows a sharp peak at 176 °C attributed to the 
phase transition from gel to liquid crystalline state.31 Similar peak 
can be observed in the physical mixture of curcumin and R-
MCM-41 samples. The peak intensity is weak due to the smaller 75 
amount of curcumin. However, in the curcumin loaded R-MCM-
41(R-MCM-41 CUR) and RR-MCM-41 (RR-MCM-41 CUR), no 
peak around the melting temperature can be found, suggesting 
that curcumin has been loaded inside the pores. This can be 
further confirmed by the the anti-proliferative effects of R-MCM-80 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  3 
41 CUR and RR MCM-41 CUR are tested in KHOS cell line by 
MTT assay. As shown in Fig. 3, both R-MCM-41 and RR-MCM-
41 themselves have no obvious toxicity to the cells at measured 
concentration range (0 -160 µg/mL). The pure curcumin kills less 
than 40% of the cells at the concentration of 15µg/mL, and no 5 
further cell death is observed at higher concentrations. The 
relatively low cell cytotoxicity of curcumin is associated with its 
low solubility and bioavailability. In contrast, R-MCM-41 CUR 
and RR-MCM-41 CUR caused significantly higher cell death 
compared to free CUR, for example at a curcumin concentration 10 
of 10 ug/mL, free CUR shows cell viability of 70% while R-
MCM-41 CUR and RR-MCM-41 CUR show cell viability of 
50% and 35%, respectively. Importantly, RR-MCM-41-CUR 
shows better cell cytotoxicity than R-MCM-41 CUR at all 
concentration tested. The IC50 value (inhibitory concentration 15 
necessary to inhibit 50% of cell growth) of R-MCM-41 CUR and 
RR-MCM-41 CUR are 11 µg/mL and 8 µg/mL, respectively. The 
IC 50 value of RR-MCM-41 CUR is around 37% lower than that 
of the R-MCM-41 CUR, consistent with the cellular entry results. 
Our results indicate that the enhanced cell toxicity of RR-MCM-20 
41 CUR is associated with its higher cellular uptake performance, 
a result of rough surface modification in comparison with R-
MCM-41 CUR. 
In summary, a new approach to increase the cellular uptake and 
drug delivery performance of MSN with a pure silica 25 
composition has been demonstrated by introducing nano-scale 
surface roughness. Rod-like MSN with rough surface show 
superior cellular uptake efficacy than traditional MSN with 
smooth surface, and this is further confirmed by the higher cell 
toxicity induced by particles loaded with curcumin. Compared to 30 
literature reports, it is a big step moving from solid nanoparticles 
to MSN due to their intrinsic nanoporous properties, which are 
more suitable for drug delivery applications as demonstrated in 
this work. Our work on the contribution of nanoscale surface 
roughness in MSN systems will lead to a series of DDS with 35 
improved performance for drug delivery. 
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